Loading
A phase 1/2 trial of Capecitabine in advanced solid tumours, run by Beijing Biostar Pharmaceuticals Co., Ltd., active and no longer recruiting.
Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05700084 by Beijing Biostar Pharmaceuticals Co., Ltd., with 84 participants enrolled, started 2023-06-09 and due to reach its primary completion in 2025-10-08. Interventions recorded: Utidelone Capsule (Part 1), Drug A Utidelone Capsule (Part 2: Group A-B), Drug A Utidelone Capsule (Part 2: Group B-A), Drug B Utidelone Injection (Part 2: Group A-B), Drug B Utidelone Injection (Part 2: Group B-A) and Capecitabine.
Shares Biostar Pharmaceuticals, Utidelone, Capecitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Capecitabine, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Capecitabine, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Capecitabine, Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Cytotoxic chemotherapy and the tag pipeline.
Shares Capecitabine, Metastatic cancer (cancer that has spread) and the tag pipeline.